Cargando…

Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening

AIMS: This study aims to compare the performance of a handheld fundus camera (Eyer) and standard tabletop fundus cameras (Visucam 500, Visucam 540, and Canon CR-2) for diabetic retinopathy and diabetic macular edema screening. METHODS: This was a multicenter, cross-sectional study that included imag...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Juliana Angélica Estevão, Nakayama, Luis Filipe, Zago Ribeiro, Lucas, de Oliveira, Talita Virgínia Fernandes, Choi, Stefano Neto Jai Hyun, Neto, Edgar Menezes, Cardoso, Viviane Santos, Dib, Sergio Atala, Melo, Gustavo Barreto, Regatieri, Caio Vinicius Saito, Malerbi, Fernando Korn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289975/
https://www.ncbi.nlm.nih.gov/pubmed/37149834
http://dx.doi.org/10.1007/s00592-023-02105-z
_version_ 1785062393652445184
author de Oliveira, Juliana Angélica Estevão
Nakayama, Luis Filipe
Zago Ribeiro, Lucas
de Oliveira, Talita Virgínia Fernandes
Choi, Stefano Neto Jai Hyun
Neto, Edgar Menezes
Cardoso, Viviane Santos
Dib, Sergio Atala
Melo, Gustavo Barreto
Regatieri, Caio Vinicius Saito
Malerbi, Fernando Korn
author_facet de Oliveira, Juliana Angélica Estevão
Nakayama, Luis Filipe
Zago Ribeiro, Lucas
de Oliveira, Talita Virgínia Fernandes
Choi, Stefano Neto Jai Hyun
Neto, Edgar Menezes
Cardoso, Viviane Santos
Dib, Sergio Atala
Melo, Gustavo Barreto
Regatieri, Caio Vinicius Saito
Malerbi, Fernando Korn
author_sort de Oliveira, Juliana Angélica Estevão
collection PubMed
description AIMS: This study aims to compare the performance of a handheld fundus camera (Eyer) and standard tabletop fundus cameras (Visucam 500, Visucam 540, and Canon CR-2) for diabetic retinopathy and diabetic macular edema screening. METHODS: This was a multicenter, cross-sectional study that included images from 327 individuals with diabetes. The participants underwent pharmacological mydriasis and fundus photography in two fields (macula and optic disk centered) with both strategies. All images were acquired by trained healthcare professionals, de-identified, and graded independently by two masked ophthalmologists, with a third senior ophthalmologist adjudicating in discordant cases. The International Classification of Diabetic Retinopathy was used for grading, and demographic data, diabetic retinopathy classification, artifacts, and image quality were compared between devices. The tabletop senior ophthalmologist adjudication label was used as the ground truth for comparative analysis. A univariate and stepwise multivariate logistic regression was performed to determine the relationship of each independent factor in referable diabetic retinopathy. RESULTS: The mean age of participants was 57.03 years (SD 16.82, 9–90 years), and the mean duration of diabetes was 16.35 years (SD 9.69, 1–60 years). Age (P = .005), diabetes duration (P = .004), body mass index (P = .005), and hypertension (P < .001) were statistically different between referable and non-referable patients. Multivariate logistic regression analysis revealed a positive association between male sex (OR 1.687) and hypertension (OR 3.603) with referable diabetic retinopathy. The agreement between devices for diabetic retinopathy classification was 73.18%, with a weighted kappa of 0.808 (almost perfect). The agreement for macular edema was 88.48%, with a kappa of 0.809 (almost perfect). For referable diabetic retinopathy, the agreement was 85.88%, with a kappa of 0.716 (substantial), sensitivity of 0.906, and specificity of 0.808. As for image quality, 84.02% of tabletop fundus camera images were gradable and 85.31% of the Eyer images were gradable. CONCLUSIONS: Our study shows that the handheld retinal camera Eyer performed comparably to standard tabletop fundus cameras for diabetic retinopathy and macular edema screening. The high agreement with tabletop devices, portability, and low costs makes the handheld retinal camera a promising tool for increasing coverage of diabetic retinopathy screening programs, particularly in low-income countries. Early diagnosis and treatment have the potential to prevent avoidable blindness, and the present validation study brings evidence that supports its contribution to diabetic retinopathy early diagnosis and treatment.
format Online
Article
Text
id pubmed-10289975
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-102899752023-06-25 Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening de Oliveira, Juliana Angélica Estevão Nakayama, Luis Filipe Zago Ribeiro, Lucas de Oliveira, Talita Virgínia Fernandes Choi, Stefano Neto Jai Hyun Neto, Edgar Menezes Cardoso, Viviane Santos Dib, Sergio Atala Melo, Gustavo Barreto Regatieri, Caio Vinicius Saito Malerbi, Fernando Korn Acta Diabetol Original Article AIMS: This study aims to compare the performance of a handheld fundus camera (Eyer) and standard tabletop fundus cameras (Visucam 500, Visucam 540, and Canon CR-2) for diabetic retinopathy and diabetic macular edema screening. METHODS: This was a multicenter, cross-sectional study that included images from 327 individuals with diabetes. The participants underwent pharmacological mydriasis and fundus photography in two fields (macula and optic disk centered) with both strategies. All images were acquired by trained healthcare professionals, de-identified, and graded independently by two masked ophthalmologists, with a third senior ophthalmologist adjudicating in discordant cases. The International Classification of Diabetic Retinopathy was used for grading, and demographic data, diabetic retinopathy classification, artifacts, and image quality were compared between devices. The tabletop senior ophthalmologist adjudication label was used as the ground truth for comparative analysis. A univariate and stepwise multivariate logistic regression was performed to determine the relationship of each independent factor in referable diabetic retinopathy. RESULTS: The mean age of participants was 57.03 years (SD 16.82, 9–90 years), and the mean duration of diabetes was 16.35 years (SD 9.69, 1–60 years). Age (P = .005), diabetes duration (P = .004), body mass index (P = .005), and hypertension (P < .001) were statistically different between referable and non-referable patients. Multivariate logistic regression analysis revealed a positive association between male sex (OR 1.687) and hypertension (OR 3.603) with referable diabetic retinopathy. The agreement between devices for diabetic retinopathy classification was 73.18%, with a weighted kappa of 0.808 (almost perfect). The agreement for macular edema was 88.48%, with a kappa of 0.809 (almost perfect). For referable diabetic retinopathy, the agreement was 85.88%, with a kappa of 0.716 (substantial), sensitivity of 0.906, and specificity of 0.808. As for image quality, 84.02% of tabletop fundus camera images were gradable and 85.31% of the Eyer images were gradable. CONCLUSIONS: Our study shows that the handheld retinal camera Eyer performed comparably to standard tabletop fundus cameras for diabetic retinopathy and macular edema screening. The high agreement with tabletop devices, portability, and low costs makes the handheld retinal camera a promising tool for increasing coverage of diabetic retinopathy screening programs, particularly in low-income countries. Early diagnosis and treatment have the potential to prevent avoidable blindness, and the present validation study brings evidence that supports its contribution to diabetic retinopathy early diagnosis and treatment. Springer Milan 2023-05-07 2023 /pmc/articles/PMC10289975/ /pubmed/37149834 http://dx.doi.org/10.1007/s00592-023-02105-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
de Oliveira, Juliana Angélica Estevão
Nakayama, Luis Filipe
Zago Ribeiro, Lucas
de Oliveira, Talita Virgínia Fernandes
Choi, Stefano Neto Jai Hyun
Neto, Edgar Menezes
Cardoso, Viviane Santos
Dib, Sergio Atala
Melo, Gustavo Barreto
Regatieri, Caio Vinicius Saito
Malerbi, Fernando Korn
Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title_full Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title_fullStr Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title_full_unstemmed Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title_short Clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
title_sort clinical validation of a smartphone-based retinal camera for diabetic retinopathy screening
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289975/
https://www.ncbi.nlm.nih.gov/pubmed/37149834
http://dx.doi.org/10.1007/s00592-023-02105-z
work_keys_str_mv AT deoliveirajulianaangelicaestevao clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT nakayamaluisfilipe clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT zagoribeirolucas clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT deoliveiratalitavirginiafernandes clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT choistefanonetojaihyun clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT netoedgarmenezes clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT cardosovivianesantos clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT dibsergioatala clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT melogustavobarreto clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT regatiericaioviniciussaito clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening
AT malerbifernandokorn clinicalvalidationofasmartphonebasedretinalcamerafordiabeticretinopathyscreening